The role of radionuclide imaging in heart failure

Journal of Nuclear Cardiology

Volumn 20, Issue 6, 2013, Pages 1173-1183

  Gulati, Vinay ^a   Ching, Gilbert ^b   Heller, Gary V ^c  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

cardiomyopathy; heart failure; mIBG imaging; Myocardial perfusion imaging; PET; SPECT

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; TETROFOSMIN TC 99M; THALLIUM 201;

ANGIOCARDIOGRAPHY; CARDIAC NEURONAL IMAGING; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; CORONARY ARTERY DISEASE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; INCIDENCE; ISCHEMIC CARDIOMYOPATHY; MORTALITY; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCINTISCANNING; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE;

HEART FAILURE; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL PERFUSION IMAGING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR FUNCTION, LEFT;

EID: 84890983585     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-013-9776-1     Document Type: Review

References (55)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics - 2013 update: A report from the American Heart Association. Circulation 2012. doi: 10.1161/CIR.0b013e31828124ad.
2. Kelly DJ, Gershlick T, Witzenbichler B, Guagliumi G, Fahy M, Dangas G, et al. Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: The HORIZONS-AMI trial. Am Heart J 2011;162:663-70.
3. Muzzarelli S, Leibundgut G, Maeder MT, Rickli H, Handschin R, Gutmann M, et al. Predictors of early readmission or death in elderly patients with heart failure. Am Heart J 2010;160:308-14.
4. Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation 2006;114:1202-13.
5. Pocock SJ, Wang D, Pfeffer MA, Yusuf S, McMurray JJV, Swedberg KB, et al. Predictors of mortality and morbidity in patients with chronic heart failure. Eur Heart J 2006;27:65-75.
6. The Multicenter Post Infarction Research Group. Risk stratification and survival after myocardial infarction. N Engl J Med 1983;309:331-6.
7. Touboul P, Andre-Fouët X, Leizorovicz A, Itti R, Lopez M, Sayegh Y, et al. Risk stratification after myocardial infarction. A reappraisal in the era of thrombolysis. The Groupe d'Etude du Pronostic de l'Infarctus du Myocarde (GREPI). Eur Heart J 1997;18:99-107.
8. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: A manifestation of coronary artery disease. Circulation 1998;97:282-9.
9. Felkar GM, Shaw LK, O'Connor CM. A standardized definition of ischemic cardiomyopathy for use in clinical research. J Am Coll Cardiol 2002;39:210-8.
10. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, Lopez-Sendon J, et al. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: Observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 2004;109:494-9.
11. Udelson JE, Shafer CD, Carrio I. Radionuclide imaging in heart failure: Assessing etiology and outcomes and implications for management. J Nucl Cardiol 2002;9:40S-52S.
12. Vaduganathan P, He ZX, Vick GW 3rd, Mahmarian JJ, Verani MS. Evaluation of left ventricular wall motion, volumes, and ejection fraction by gated myocardial tomography with technetium 99m-labeled tetrofosmin: A comparison with cine magnetic resonance imaging. J Nucl Cardiol 1999;6:3-10.
13. Bulkley BH, Hutchins GM, Bailey I, Strauss HW, Pitt B. Thallium 201 imaging and gated cardiac blood pool scans in patients with ischemic and idiopathic congestive cardiomyopathy. A clinical and pathologic study. Circulation 1977;55:753-60.
14. Kapur A, Latus KA, Davies G, Dhawan RT, Eastick S, Jarritt PH, et al. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: The ROBUST study. Eur J Nucl Med Mol Imaging 2002;29:1608-16.
15. Danias PG, Ahlberg AW, Clark BA III, Messineo F, Levine MG, McGill CC, et al. Combined assessment of myocardial perfusion and left ventricular function with exercise technetium-99m sestamibi gated single-photon emission computed tomography can differentiate between ischemic and nonischemic dilated cardiomyopathy. Am J Cardiol 1998;82:1253-8.
16. Danias PG, Papaioannou GI, Ahlberg AW, O'Sullivan DM, Mann A, Boden WE, et al. Usefulness of electrocardiographic-gated stress technetium-99m sestamibi single-photon emission computed tomography to differentiate ischemic from nonischemic cardiomyopathy. Am J Cardiol 2004;94:14-9.
17. Yao SS, Qureshi E, Nichols K, Diamond GA, Depuey EG, Rozanski A. Prospective validation of a quantitative method for differentiating ischemic versus nonischemic cardiomyopathy by technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. Clin Cardiol 2004;27:615-20.
18. Wu YW, Yen RF, Chieng PU, Huang PJ. Tl-201 myocardial SPECT in differentiation of ischemic from nonischemic dilated cardiomyopathy in patients with left ventricular dysfunction. J Nucl Cardiol 2003;10:369-74.
19. Soman P, Lahiri A, Mieres JH, et al. Etiology and pathophysiology of new-onset heart failure: Evaluation by myocardial perfusion imaging. J Nucl Cardiol 2009;16:82-91.
20. Klocke FJ, Baird MG, Lorell BH, Bateman TM, Messer JV, Berman DS, et al. ACC/AHA/ASNC guidelines for the clinical use of cardiac radionuclide imaging-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASNC committee to revise the 1995 guidelines for the clinical use of cardiac radionuclide imaging). J Am Coll Cardiol 2003;42:1318-33.
21. Eisenberg JD, Sobel BE, Geltman EM. Differentiation of ischemic from nonischemic cardiomyopathy with positron emission tomography. Am J Cardiol 1987;59:1410-4.
22. Mody FV, Brunken RC, Stevenson LW, Nienaber CA, Phelps ME, Schelbert HR. Differentiating cardiomyopathy of coronary artery disease from nonischemic dilated cardiomyopathy utilizing positron emission tomography. J Am Coll Cardiol 1991;17:373-83.
23. Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA, Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: Comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol 2006;13:24-33.
24. Dunn RF, Uren RF, Sadick N, Bautovich G, McLaughlin A, Hiroe M, et al. Comparison of thallium-201 scanning in idiopathic dilated cardiomyopathy and severe coronary artery disease. Circulation 1982;66:840-5.
25. Iles L, Pfluger H, Lefkovits L, Butler MJ, Kistler PM, Kaye DM, et al. Myocardial fibrosis predicts appropriate device therapy with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol 2011;57:821-8.
26. Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation 1999;100:1992-2002.
27. McCrohon JA, Moon JCC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation 2003;108:54-9.
28. Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol 2006;48:1977-85.
29. Nishimura T, Nakajima K, Kusuoka H, Yamashina A, Nishimura S. Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial perfusion SPECT: J-ACCESS study. Eur J Nucl Med Mol Imaging 2008;35:319-28.
30. Hachamovitch R, Berman DS, Shaw LJ, Kiat H, Cohen I, Cabico JA, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for the prediction of cardiac death: Differential stratification for risk of cardiac death and myocardial infarction. Circulation 1998;97:535-43.
31. Piccini JP, Horton JR, Shaw LK, Al-Khatib SM, Lee KL, Iskandrian AE, et al. Single-photon emission computed tomography myocardial perfusion defects are associated with an increased risk of all-cause death, cardiovascular death, and sudden cardiac death. Circ Cardiovasc Imaging 2008;1:180-8.
32. Ahlberg AW, Kazi FA, Azemi T, Katten DM, O'Sullivan DM, Papaioannou GI, et al. Usefulness of stress gated technetium-99m single photon emission computed tomographic myocardial perfusion imaging for the prediction of cardiac death in patients with moderate to severe left ventricular systolic dysfunction and suspected coronary artery disease. Am J Cardiol 2012;109:26-30.
33. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 2002;39:1151-8.
34. Tio RA, Dabeshlim A, Siebelink HM, de Sutter J, Hillege HL, Zeebregts CJ, et al. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med 2009;50:214-9.
35. Neglia D, Parodi O, Gallopin M, Sambuceti G, Giorgetti A, Pratali L, et al. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion inpatients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography. Circulation 1995;92:796-804.
36. Neglia D, Michelassi C, Trivieri MG, Sambuceti G, Giorgetti A, Pratali L, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002;105:186-93.
37. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med 2003;349:1027-35.
38. Verrier RL, Antzelevich C. Autonomic aspects of arrhythmogenesis: The enduring and the new. Curr Opin Cardiol 2004;19:2-11.
39. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85.
40. Sisson JC, Wieland DM. Radiolabelled meta-iodobenzyl guanidine pharmacology: Pharmacology and clinical studies. Am J Physiol Imaging 1986;1:96-103.
41. Yamashina S, Yamazaki J. Neuronal imaging using SPECT. Eur J Nucl Med Mol Imaging 2007;34:939-50.
42. Chen GP, Tabibiazar R, Branch KR, Link JM, Caldwell JH. Cardiac receptor physiology and imaging: An update. J Nucl Cardiol 2005;12:714-30.
43. 123I-mIBG scintigraphic study. J Nucl Med 2000;41:845-51.
44. Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzyl-guanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging 2005;32:186-94.
45. Bardy G, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
46. Buxton AE, Lee KL, Hafley GE, Pires LA, Fisher JD, Gold MR, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: Lessons from the MUSTT study. J Am Coll Cardiol 2007;50:1150-7.
47. Arora A, Ferrick KJ, Nakata T, Kaplan RC, Rozengarten M, Latif F, et al. I-123 mIBG imaging and heart rate variability analysis to predict the need for an implantable cardioverter defibrillator. J Nucl Cardiol 2003;10:121-31.
48. Nagahara D, Nakata T, Hashimoto A, Wakabayashi T, Kyuma M, Noda R, et al. Predicting the need for an implantable cardioverted defibrillator using cardiac metaiodobenzylguanidine activity together with plasma natriuretic peptide concentration or left ventricular function. J Nucl Med 2008;49:225-33.
49. Nishisato K, Hashimoto A, Nakata T, Doi T, Yamamoto H, Nagahara D, et al. Impaired cardiac sympathetic innervation and myocardial perfusion are related to lethal arrhythmia: Quantification of cardiac tracers in patients with ICDs. J Nucl Med 2010;51:1241-9.
50. Merlet P, Valette H, Dubois-Randé JL, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. J Nucl Med 1992;33:471-7.
51. Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by mIBG in patients with failing and non failing hearts. J Nucl Cardiol 1998;5:579-90.
52. Agostini D, Verbene HJ, Burchert W, Knuuti J, Povinec P, Sambuceti G, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: Insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging 2008;35:535-46.
53. Jacobson A, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Cardiol 2010;55:2212-21.
54. 123I-mIBG sympathetic innervation imaging improves prediction of arrhythmic events in non-ischemic cardiomyopathy patients: Substudy from the ADMIRE-HF trial. J Nucl Cardiol 2013. doi: 10.1007/s12350-013-9750-y.
55. Nakata T, Nakajima K, Yamashina S, Yamada T, Momose M, Kasama S, et al. A pooled analysis of multicenter cohort studies of 123-I-mIBG imaging of sympathetic innervation for assessment of long-term prognosis in heart failure. J Am Coll Cardiol Imaging 2013;6:772-84.